Premium
Fallberichte. Sekundäre Prophylaxe mit liposomalem Amphotericin B nach invasiver Aspergillose nach antileukämischer Chemotherapie
Author(s) -
Mele L.,
Pagano L.,
Equitani F.,
Leone G.
Publication year - 2001
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1046/j.1439-0507.2001.00644.x
Subject(s) - medicine , amphotericin b , aspergillosis , chemotherapy , malignancy , mycosis , toxicity , surgery , antifungal , dermatology , immunology
Summary. We report our recent experience with two cases of invasive pulmonary aspergillosis in patients who were both undergoing chemotherapy, one for acute myeloid leukaemia and the other for primary amyloidosis. Both patients had bad prognostic factors and were in very poor clinical condition, but both recovered from infection after a prolonged therapy with liposomal amphotericin B (AmBisome ® ) without signs of toxicity.